spacer
home > ebr > summer 2004 > the declaration of helsinki: protecting patient rights in biomedical research drug discovery technologies
PUBLICATIONS
European Biopharmaceutical Review

The Declaration of Helsinki: Protecting Patient Rights in Biomedical Research Drug Discovery Technologies

The Declaration of Helsinki is the world's most widely recognised source of ethical guidance for biomedical research. Since its adoption in 1964, it has become the pre-eminent ethical guidance on health care research. Adherence to it is required by the World Health Organization and by many national governments, who refer to its provisions in their legislation. Scientists are often criticised for carrying out research in developing countries without following the Declaration, and some organisations and companies sponsoring research request that researchers receiving funding abide by its requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Delon Human, Secretary General of the World Medical Association

Dr Delon Human has been Secretary General of the WMA since 1998. He is a former family physician from Pretoria, South Africa and a past president of a branch of the Medical Association of South Africa. He qualified as a family practitioner in 1985 and spent some time at the John Radcliffe Hospital in Oxford, England, conducting research in paediatric endocrinology. He then gained two further Masters degrees in Family Medicine and a Diploma in Child Health. In addition to his medical qualifications, Dr Human has also obtained an MBA from the European Business School.

spacer
Dr Delon Human
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize


More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement